Search results
Showing 1 to 50 of 58 results for durvalumab
Technology appraisal and highly specialised technologies appeals
Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.
Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.
Show all sections
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.
Evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer in adults.
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Show all sections
More than 400 people could benefit from life-extending advanced lung cancer treatment
Durvalumab recommended as an option for treating non-small-cell lung cancer.
Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZeneca withdrew its evidence submission.
Show all sections
Sections for TA662
Discontinued Reference number: GID-TA10186
Discontinued Reference number: GID-TA10875
Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]
Discontinued Reference number: GID-TA10963
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
Discontinued Reference number: GID-TA10633
Discontinued Reference number: GID-TA10473
Discontinued Reference number: GID-TA10474
Discontinued Reference number: GID-TA10616
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
Discontinued Reference number: GID-TA10617
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development Reference number: GID-NG10404 Expected publication date: TBC
Discontinued Reference number: GID-TA10318
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued Reference number: GID-TA10324
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development Reference number: GID-TA11569 Expected publication date: TBC
Discontinued Reference number: GID-TA11289
Awaiting development Reference number: GID-TA11517 Expected publication date: TBC
Awaiting development Reference number: GID-TA11281 Expected publication date: TBC
In development Reference number: GID-TA11340 Expected publication date: TBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Discontinued Reference number: GID-TA11041
Discontinued Reference number: GID-TA10783
Awaiting development Reference number: GID-TA11019 Expected publication date: TBC
Awaiting development Reference number: GID-TA10911 Expected publication date: TBC
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]
Awaiting development Reference number: GID-TA11076 Expected publication date: TBC
Awaiting development Reference number: GID-TA11222 Expected publication date: TBC
Awaiting development Reference number: GID-TA10967 Expected publication date: TBC
Awaiting development Reference number: GID-TA11161 Expected publication date: TBC
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]
Discontinued Reference number: GID-TA10394
Discontinued Reference number: GID-TA10422
In development Reference number: GID-TA10748 Expected publication date: TBC
In development Reference number: GID-TA11115 Expected publication date: TBC
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
Awaiting development Reference number: GID-TA11828 Expected publication date: TBC
In development Reference number: GID-TA11440 Expected publication date: TBC
In development Reference number: GID-TA11214 Expected publication date: TBC
Awaiting development Reference number: GID-TA11671 Expected publication date: TBC
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
In development Reference number: GID-TA11232 Expected publication date: 08 April 2026